Sight Sciences, Inc. Financials
Sight Sciences, Inc. (SGHT) reported $77.4M in revenue for fiscal year 2025, down 3.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Sight Sciences remains a high-gross-margin business whose loss reduction is coming from overhead cuts, not renewed sales momentum.
From FY2023 to FY2025, operating loss improved by$20.2M even as revenue slipped4.6% , so the model got less expensive before it got bigger. Because gross margin stayed above85% , that improvement points more to overhead discipline than to a demand rebound, with SG&A doing most of the work.
With
In FY2025, free cash flow almost matched operating cash flow because capital spending was only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Sight Sciences, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Sight Sciences, Inc. scores 1.31, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($455.0M) relative to total liabilities ($51.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sight Sciences, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Sight Sciences, Inc. reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Sight Sciences, Inc. reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Sight Sciences, Inc. generated $77.4M in revenue in fiscal year 2025. This represents a decrease of 3.1% from the prior year.
Sight Sciences, Inc.'s EBITDA was -$36.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26.5% from the prior year.
Sight Sciences, Inc. reported -$38.4M in net income in fiscal year 2025. This represents an increase of 25.4% from the prior year.
Sight Sciences, Inc. earned -$0.74 per diluted share (EPS) in fiscal year 2025. This represents an increase of 28.2% from the prior year.
Cash & Balance Sheet
Sight Sciences, Inc. recorded an outflow of $29.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 31.6% from the prior year.
Sight Sciences, Inc. held $92.0M in cash against $40.3M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Sight Sciences, Inc.'s gross margin was 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.
Sight Sciences, Inc.'s operating margin was -47.9% in fiscal year 2025, reflecting core business profitability. This is up 15.3 percentage points from the prior year.
Sight Sciences, Inc.'s net profit margin was -49.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 14.8 percentage points from the prior year.
Sight Sciences, Inc.'s ROE was -60.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.2 percentage points from the prior year.
Capital Allocation
Sight Sciences, Inc. invested $14.6M in research and development in fiscal year 2025. This represents a decrease of 18.8% from the prior year.
Sight Sciences, Inc. invested $224K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 41.8% from the prior year.
Not reported for fiscal year 2025.
SGHT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $83.4M | $77.4M-3.1% | $79.9M-1.5% | $81.1M+13.6% | $71.3M+45.7% | $49.0M+77.1% | $27.6M |
| Cost of Revenue | $10.0M | $10.7M-7.6% | $11.6M-2.5% | $11.9M-3.9% | $12.4M+43.6% | $8.6M-6.5% | $9.2M |
| Gross Profit | $73.3M | $66.7M-2.4% | $68.3M-1.3% | $69.2M+17.3% | $59.0M+46.2% | $40.3M+118.9% | $18.4M |
| R&D Expenses | $10.8M | $14.6M-18.8% | $18.0M+2.5% | $17.6M-23.2% | $22.9M+46.2% | $15.6M+76.2% | $8.9M |
| SG&A Expenses | $90.4M | $89.2M-11.6% | $100.8M-7.4% | $108.9M-9.3% | $120.1M+57.6% | $76.2M+82.5% | $41.7M |
| Operating Income | -$27.9M | -$37.1M+26.6% | -$50.5M+11.8% | -$57.3M+31.8% | -$84.0M-63.1% | -$51.5M-59.9% | -$32.2M |
| Interest Expense | $5.2M | $5.1M+10.3% | $4.7M-13.8% | $5.4M+21.1% | $4.5M+2.3% | $4.4M+81.7% | $2.4M |
| Income Tax | -$32K | $10K-95.8% | $236K+114.5% | $110K+134.0% | $47K-75.0% | $188K+208.2% | $61K |
| Net Income | -$29.8M | -$38.4M+25.4% | -$51.5M+7.3% | -$55.5M+35.6% | -$86.2M-37.0% | -$63.0M-81.5% | -$34.7M |
| EPS (Diluted) | — | -$0.74+28.2% | -$1.03+9.6% | -$1.14+36.7% | -$1.80 | -$2.36 | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SGHT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $115.3M-19.3% | $142.8M-14.3% | $166.7M-21.8% | $213.1M-24.0% | $280.2M+284.8% | $72.8M |
| Current Assets | $112.7M-19.3% | $139.8M-14.2% | $162.9M-22.3% | $209.7M-24.3% | $277.0M+292.2% | $70.6M |
| Cash & Equivalents | $92.0M-23.6% | $120.4M-12.9% | $138.1M-25.3% | $185.0M-29.0% | $260.7M+323.8% | $61.5M |
| Inventory | $7.8M+22.8% | $6.3M-19.4% | $7.8M+28.4% | $6.1M+75.9% | $3.5M+33.8% | $2.6M |
| Accounts Receivable | $9.7M-9.7% | $10.8M-24.5% | $14.3M-5.7% | $15.1M+73.9% | $8.7M+62.4% | $5.4M |
| Total Liabilities | $51.4M-7.2% | $55.3M+19.1% | $46.4M-12.4% | $53.0M+10.2% | $48.1M-70.3% | $161.7M |
| Current Liabilities | $11.0M-28.7% | $15.5M+26.2% | $12.3M-31.2% | $17.8M+31.9% | $13.5M+45.0% | $9.3M |
| Long-Term Debt | $40.3M+2.4% | $39.4M+24.1% | $31.7M-4.8% | $33.3M+2.0% | $32.7M+2.2% | $32.0M |
| Total Equity | $63.9M-26.9% | $87.5M-27.2% | $120.2M-24.9% | $160.1M-31.0% | $232.1M+361.2% | -$88.8M |
| Retained Earnings | -$384.7M-11.1% | -$346.3M-17.5% | -$294.8M-23.2% | -$239.2M-56.4% | -$153.0M-69.9% | -$90.0M |
Not reported in any period shown, so not listed: Goodwill.
SGHT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.2M | -$29.7M-32.9% | -$22.4M+52.6% | -$47.2M+37.9% | -$76.0M-44.6% | -$52.5M-63.3% | -$32.2M |
| Capital Expenditures | $93K | $224K-41.8% | $385K-51.3% | $791K-18.5% | $970K+19.3% | $813K-14.7% | $953K |
| Free Cash Flow | -$23.6M | -$29.9M-31.6% | -$22.7M+52.6% | -$48.0M+37.6% | -$76.9M-44.2% | -$53.4M-61.1% | -$33.1M |
| Investing Cash Flow | -$93K | -$224K+41.8% | -$385K+51.3% | -$791K+18.5% | -$970K-19.3% | -$813K+14.7% | -$953K |
| Financing Cash Flow | $1.9M | $1.8M-63.9% | $5.0M+349.6% | $1.1M-11.5% | $1.2M-99.5% | $252.5M+244.0% | $73.4M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
SGHT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Gross Margin | 86.2%+0.7pp | 85.5%+0.2pp | 85.3%+2.7pp | 82.7%+0.3pp | 82.4%+15.7pp | 66.7% |
| Operating Margin | -47.9%+15.3pp | -63.3%+7.4pp | -70.7% | -117.7% | -105.2% | -116.5% |
| Net Margin | -49.7%+14.8pp | -64.5%+4.0pp | -68.5% | -120.9% | -128.6% | -125.5% |
| Return on Equity | -60.1%-1.2pp | -58.9%-12.6pp | -46.2%+7.7pp | -53.9%-26.7pp | -27.1% | N/A |
| Return on Assets | -33.3%+2.7pp | -36.1%-2.7pp | -33.3%+7.2pp | -40.5%-18.0pp | -22.5%+25.2pp | -47.6% |
| Current Ratio | 10.22+1.2x | 9.04-4.3x | 13.29+1.5x | 11.77-8.7x | 20.52+12.9x | 7.58 |
| Debt-to-Equity | 0.63+0.2x | 0.45+0.2x | 0.26+0.1x | 0.21+0.1x | 0.14 | N/A |
| FCF Margin | -38.7%-10.2pp | -28.5%+30.7pp | -59.2% | -107.9% | -109.0% | -119.8% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Sight Sciences, Inc. Ranks
Frequently Asked Questions
What is Sight Sciences, Inc.'s annual revenue?
Sight Sciences, Inc. (SGHT) reported $77.4M in total revenue for fiscal year 2025. This represents a -3.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sight Sciences, Inc.'s revenue growing?
Sight Sciences, Inc. (SGHT) revenue declined by 3.1% year-over-year, from $79.9M to $77.4M in fiscal year 2025.
Is Sight Sciences, Inc. profitable?
No, Sight Sciences, Inc. (SGHT) reported a net income of -$38.4M in fiscal year 2025, with a net profit margin of -49.7%.
What is Sight Sciences, Inc.'s EBITDA?
Sight Sciences, Inc. (SGHT) had EBITDA of -$36.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Sight Sciences, Inc. have?
As of fiscal year 2025, Sight Sciences, Inc. (SGHT) had $92.0M in cash and equivalents against $40.3M in long-term debt.
What is Sight Sciences, Inc.'s gross margin?
Sight Sciences, Inc. (SGHT) had a gross margin of 86.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sight Sciences, Inc.'s operating margin?
Sight Sciences, Inc. (SGHT) had an operating margin of -47.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Sight Sciences, Inc.'s net profit margin?
Sight Sciences, Inc. (SGHT) had a net profit margin of -49.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Sight Sciences, Inc.'s return on equity (ROE)?
Sight Sciences, Inc. (SGHT) has a return on equity of -60.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Sight Sciences, Inc.'s free cash flow?
Sight Sciences, Inc. (SGHT) recorded an outflow of $29.9M in free cash flow during fiscal year 2025. This represents a -31.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sight Sciences, Inc.'s operating cash flow?
Sight Sciences, Inc. (SGHT) recorded an outflow of $29.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sight Sciences, Inc.'s total assets?
Sight Sciences, Inc. (SGHT) had $115.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sight Sciences, Inc.'s capital expenditures?
Sight Sciences, Inc. (SGHT) invested $224K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sight Sciences, Inc. spend on research and development?
Sight Sciences, Inc. (SGHT) invested $14.6M in research and development during fiscal year 2025.
What is Sight Sciences, Inc.'s current ratio?
Sight Sciences, Inc. (SGHT) had a current ratio of 10.22 as of fiscal year 2025, which is generally considered healthy.
What is Sight Sciences, Inc.'s debt-to-equity ratio?
Sight Sciences, Inc. (SGHT) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sight Sciences, Inc.'s return on assets (ROA)?
Sight Sciences, Inc. (SGHT) had a return on assets of -33.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Sight Sciences, Inc.'s cash runway?
Based on fiscal year 2025 data, Sight Sciences, Inc. (SGHT) had $92.0M in cash against an annual operating cash burn of $29.7M. This gives an estimated cash runway of approximately 37 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sight Sciences, Inc.'s Altman Z-Score?
Sight Sciences, Inc. (SGHT) has an Altman Z-Score of 1.31, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sight Sciences, Inc.'s Piotroski F-Score?
Sight Sciences, Inc. (SGHT) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sight Sciences, Inc.'s earnings high quality?
Sight Sciences, Inc. (SGHT) reported a net loss of $38.4M while operations used $29.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sight Sciences, Inc. cover its interest payments?
Sight Sciences, Inc. (SGHT) reported an operating loss of $37.1M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sight Sciences, Inc.?
Sight Sciences, Inc. (SGHT) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.